{
    "nct_id": "NCT04943900",
    "official_title": "A Phase 1 Study of BMS-986416 Alone and in Combination With Nivolumab in Select Solid Tumors",
    "inclusion_criteria": "* Participants with histologically or cytologically confirmed locally advanced unresectable, metastatic, or recurrent select solid tumor\n* Eligible tumor types Non-small cell lung cancer (NSCLC), Urothelial carcinoma (UC), Squamous cell carcinoma of the head and neck (SCCHN), Hepatocellular carcinoma (HCC), Microsatellite-stable colorectal carcinoma (MSS CRC), or Pancreatic ductal adenocarcinoma (PDAC)\n* Resistant/refractory to or intolerant of existing standard therapies known to provide clinical benefit\n* Measurable disease per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v 1.1)\n* Disease amenable to serial biopsy\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Uncontrolled or significant cardiovascular disease\n* Known connective tissue disease such as Marfan, Ehlers-Danlos, or Loeys-Dietz syndrome\n* Medical requirement for chronic anticoagulant or antiplatelet agents (except low-dose aspirin, which is permitted)\n\nOther protocol-defined inclusion/exclusion criteria apply",
    "miscellaneous_criteria": ""
}